Literature DB >> 22161024

Amplification of thymosin beta 10 and AKAP13 genes in metastatic and aggressive papillary thyroid carcinomas.

Liliána Z Fehér1, Gábor Pocsay, László Krenács, Agnes Zvara, Enikő Bagdi, Réka Pocsay, Géza Lukács, Ferenc Győry, Andrea Gazdag, Erzsébet Tarkó, László G Puskás.   

Abstract

Papillary thyroid carcinoma (PTC) is the most common well-differentiated thyroid cancer. Although the great majority of the cases exhibit an indolent clinical course, some of them develop local invasion with distant metastasis, and a few cases transform into undifferentiated/anaplastic thyroid carcinoma with a rapidly lethal course. To identify gene copy number alterations predictive of metastatic potential or aggressive transformation, array-based comparative genomic hybridization (CGH-array) was performed in 43 PTC cases. Formalin-fixed and paraffin-embedded samples from primary tumours of 16 cases without metastasis, 14 cases with only regional lymph node metastasis, and 13 cases with distant metastasis, recurrence or extrathyroid extension were analysed. The CGH-array and confirmatory quantitative real-time PCR results identified the deletion of the EIF4EBP3 and TRAK2 gene loci, while amplification of thymosin beta 10 (TB10) and Tre-2 oncogene regions were observed as general markers for PTC. Although there have been several studies implicating TB10 as a specific marker based on gene expression data, our study is the first to report on genomic amplification. Although no significant difference could be detected between the good and bad prognosis cases in the A-kinase anchor protein 13 (AKAP13) gene region, it was discriminative markers for metastasis. Amplification in the AKAP13 region was demonstrated in 42.9% and 15.4% of the cases with local or with distant metastasis, respectively, while no amplification was detected in non-metastatic cases. AKAP13 and TB10 regions may represent potential new genomic markers for PTC and cancer progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22161024     DOI: 10.1007/s12253-011-9467-7

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  65 in total

1.  Keratinocyte growth factor 1 inhibits wound edge epithelial cell apoptosis in vitro.

Authors:  James D Firth; Edward E Putnins
Journal:  J Invest Dermatol       Date:  2004-01       Impact factor: 8.551

2.  Improved DOP-PCR-based representational whole-genome amplification using quantitative real-time PCR.

Authors:  Liliána Z Fehér; Margit Balázs; János Z Kelemen; Agnes Zvara; István Németh; Zoltán Varga-Orvos; László G Puskás
Journal:  Diagn Mol Pathol       Date:  2006-03

3.  A second field metachronous Merkel cell carcinoma of the lip and the palatine tonsil confirmed by microarray-based comparative genomic hybridisation.

Authors:  Judit Nagy; Liliána Z Fehér; István Sonkodi; József Lesznyák; Béla Iványi; László G Puskás
Journal:  Virchows Arch       Date:  2005-02-25       Impact factor: 4.064

4.  Expression of keratinocyte growth factor and its receptor in human breast cancer: its inhibitory role in the induction of apoptosis possibly through the overexpression of Bcl-2.

Authors:  Yoshitaka Hishikawa; Naóe Tamaru; Kuniaki Ejima; Tomayoshi Hayashi; Takehiko Koji
Journal:  Arch Histol Cytol       Date:  2004-12

5.  The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.

Authors:  R W Tsang; J D Brierley; W J Simpson; T Panzarella; M K Gospodarowicz; S B Sutcliffe
Journal:  Cancer       Date:  1998-01-15       Impact factor: 6.860

6.  Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991.

Authors:  F D Gilliland; W C Hunt; D M Morris; C R Key
Journal:  Cancer       Date:  1997-02-01       Impact factor: 6.860

7.  Thymosin beta-10 gene expression as a possible tool in diagnosis of thyroid neoplasias.

Authors:  Gennaro Chiappetta; Francesca Pentimalli; Mario Monaco; Monica Fedele; Rosa Pasquinelli; Giovanna Maria Pierantoni; Maria Teresa Ribecco; Giovanni Santelli; Daniela Califano; Luciano Pezzullo; Alfredo Fusco
Journal:  Oncol Rep       Date:  2004-08       Impact factor: 3.906

8.  Anchoring of both PKA and 14-3-3 inhibits the Rho-GEF activity of the AKAP-Lbc signaling complex.

Authors:  Dario Diviani; Liliane Abuin; Susanna Cotecchia; Laetitia Pansier
Journal:  EMBO J       Date:  2004-07-01       Impact factor: 11.598

9.  Array CGH demonstrates characteristic aberration signatures in human papillary thyroid carcinomas governed by RET/PTC.

Authors:  K Unger; E Malisch; G Thomas; H Braselmann; A Walch; G Jackl; P Lewis; E Lengfelder; T Bogdanova; J Wienberg; H Zitzelsberger
Journal:  Oncogene       Date:  2008-04-14       Impact factor: 9.867

10.  The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients.

Authors:  N A Samaan; P N Schultz; R C Hickey; H Goepfert; T P Haynie; D A Johnston; N G Ordonez
Journal:  J Clin Endocrinol Metab       Date:  1992-09       Impact factor: 5.958

View more
  9 in total

1.  Combined Proteomics and Transcriptomics Identifies Carboxypeptidase B1 and Nuclear Factor κB (NF-κB) Associated Proteins as Putative Biomarkers of Metastasis in Low Grade Breast Cancer.

Authors:  Pavel Bouchal; Monika Dvořáková; Theodoros Roumeliotis; Zbyněk Bortlíček; Ivana Ihnatová; Iva Procházková; Jenny T C Ho; Josef Maryáš; Hana Imrichová; Eva Budinská; Rostislav Vyzula; Spiros D Garbis; Bořivoj Vojtěšek; Rudolf Nenutil
Journal:  Mol Cell Proteomics       Date:  2015-04-22       Impact factor: 5.911

2.  Identification of RAB2A and PRDX1 as the potential biomarkers for oral squamous cell carcinoma using mass spectrometry-based comparative proteomic approach.

Authors:  Kaushik Kumar Dey; Ipsita Pal; Rashmi Bharti; Goutam Dey; B N Prashanth Kumar; Shashi Rajput; Aditya Parekh; Sheetal Parida; Priyanka Halder; Indranil Kulavi; Mahitosh Mandal
Journal:  Tumour Biol       Date:  2015-07-11

3.  Somatic amplifications and deletions in genome of papillary thyroid carcinomas.

Authors:  Nadia Passon; Elisa Bregant; Marialuisa Sponziello; Maria Dima; Francesca Rosignolo; Cosimo Durante; Marilena Celano; Diego Russo; Sebastiano Filetti; Giuseppe Damante
Journal:  Endocrine       Date:  2015-04-12       Impact factor: 3.633

4.  Immunoreactivity for thymosin beta 4 and thymosin beta 10 in the adult rat oro-gastro-intestinal tract.

Authors:  S Nemolato; J Ekstrom; T Cabras; C Gerosa; D Fanni; E Di Felice; A Locci; I Messana; M Castagnola; G Faa
Journal:  Eur J Histochem       Date:  2013-05-07       Impact factor: 3.188

5.  Suppression of thymosin β10 increases cell migration and metastasis of cholangiocarcinoma.

Authors:  Sirinapa Sribenja; Kanlayanee Sawanyawisuth; Ratthaphol Kraiklang; Chaisiri Wongkham; Kulthida Vaeteewoottacharn; Sumalee Obchoei; Qizhi Yao; Sopit Wongkham; Changyi Chen
Journal:  BMC Cancer       Date:  2013-09-23       Impact factor: 4.430

6.  Generation of metastatic melanoma specific antibodies by affinity purification.

Authors:  Birgit Schütz; Anita Koppensteiner; David Schörghofer; Katharina Kinslechner; Gerald Timelthaler; Robert Eferl; Markus Hengstschläger; Albert Missbichler; Harald Hundsberger; Mario Mikula
Journal:  Sci Rep       Date:  2016-11-17       Impact factor: 4.379

7.  [Thymosin beta 10 prompted the VEGF-C expression in lung cancer cell].

Authors:  Zixuan Li; Lianyue Qu; Hongshan Zhong; Ke Xu; Xueshan Qiu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-05

8.  Deer thymosin beta 10 functions as a novel factor for angiogenesis and chondrogenesis during antler growth and regeneration.

Authors:  Wei Zhang; Wenhui Chu; Qingxiu Liu; Dawn Coates; Yudong Shang; Chunyi Li
Journal:  Stem Cell Res Ther       Date:  2018-06-19       Impact factor: 6.832

9.  High expression of thymosin beta 10 predicts poor prognosis for hepatocellular carcinoma after hepatectomy.

Authors:  Haoyuan Wang; Shanshan Jiang; Yaojun Zhang; Ke Pan; Jianchuan Xia; Minshan Chen
Journal:  World J Surg Oncol       Date:  2014-07-18       Impact factor: 2.754

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.